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Abstract  19 
 20 
Artemisinin combination therapies (ACTs) are currently the first line drugs for treating 21 
uncomplicated falciparum malaria, the most deadly of the human malarias. Malaria parasite 22 
clearance rates estimated from patients’ blood following ACT treatment have been widely 23 
adopted as a measure of drug effectiveness and as surveillance tools for detecting the 24 
presence of potential artemisinin drug resistance. This metric has not been investigated in 25 
detail, nor have its properties or potential shortcomings been identified. Herein, the 26 
pharmacology of drug treatment, parasite biology, and human immunity are combined to 27 
investigate the dynamics of parasite clearance following ACT treatment. This approach 28 
parsimoniously recovers the principal clinical features and dynamics of clearance. Human 29 
immunity is the primary determinant of clearance rates unless, or until, artemisinin killing has 30 
fallen to near-ineffective levels. Clearance rates are therefore highly insensitive metrics for 31 
surveillance that may lead to over-confidence as even quite substantial reductions in drug 32 
sensitivity may not be detected as slower clearance rates. Equally serious is the use of 33 
clearance rates to quantify the impact of ACT regime changes as this strategy will plausibly 34 
miss even very substantial increases in drug effectiveness. In particular, the malaria 35 
community may be missing the opportunity to dramatically increase ACT effectiveness 36 
through changes in regimen, particularly through a switch to twice-daily regimens and/or 37 
increases in artemisinin dosing levels. The malaria community therefore appears over reliant 38 
on a single metric of drug effectiveness, parasite clearance rate that has significant and 39 
serious shortcomings. 40 
  41 
42 
3 
 
Introduction 43 
 44 
The timely provision of effective antimalarial drugs is a public health priority in most of the 45 
developing world (1). The current generation of antimalarial drugs centre on artemisinin-46 
based combination therapies (ACTs) and recent reports that tolerance and/or resistance is 47 
evolving to artemisinins (e.g. (2-7)) have caused considerable concerns (e.g. (8-12)). ACTs 48 
currently remain largely effective in clearing malaria infections, but reduced parasite 49 
clearance rates (i.e. the rate at which parasitaemia declines after treatment (13)) have been 50 
widely interpreted as indicating the presence of reduced parasite drug sensitivity to the 51 
artemisinin component, and hence indicative of the early stages of resistance (op cit). Parasite 52 
clearance rates have also been used to evaluate the likely clinical impact of alterations in 53 
artemisinin or ACT dosing regimens (e.g. (14)) that may be able to increase ACT 54 
effectiveness and hence reduce the threat of resistance. It would therefore seem reasonable to 55 
expect that parasite clearance rates are a well validated, demonstrably robust measure of drug 56 
effectiveness and resistance. Unfortunately, this appears not to be the case, as reflected in 57 
concerns raised in recent commentaries (15-17). Herein, the pharmacology of drug action, 58 
parasite biology and human immunity are combined to investigate the dynamics of parasite 59 
clearance following ACT treatment. This reveals the basic properties of the metric and allows 60 
critical review of the use of parasite clearance rates as an indicator of drug effectiveness and 61 
resistance. 62 
 63 
The parasite clearance phenotype is as follows. The microscopically observed number of 64 
infected red blood cells (iRBCs) following ACT treatment fluctuates for a brief period of 65 
around 6 to 20 hours post-treatment (18-20). These initial fluctuations are usually explained 66 
by the imbalance between the introduction of new merozoites into the circulation from 67 
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sequestered schizonts and the depletion of circulating iRBCs through sequestration. This is 68 
then followed by a sustained, linear decline in log iRBC numbers over the next 40 to 60 hours 69 
(18-20) . The slope of this linear decline is the “parasite clearance rate”, and there are well-70 
established protocols for its measurement (e.g. (20, 21)). One critical point to note is that 71 
artemisinins have a very short half-life of around 40 minutes in humans (22) and are present 72 
as short pulses of active concentrations for only 4 to 6 hours post treatment (23). This means 73 
the initial artemisinin pulse has effectively been eliminated from the circulating blood by the 74 
time the linear clearance dynamics (which define parasite clearance rates) occur. The 75 
practical consequence is that iRBC clearance rates measured more than ~6 hours post-76 
treatment cannot be a direct measure of artemisinin effectiveness in its first pulse (because 77 
the artemisinin is no longer present), but must be an indirect proxy measure. Importantly, the 78 
subsequent short pulses of artemisinin treatment in an ACT regimen, typically at 24 and 48 79 
hours after first treatment, do not usually show as increased clearance rates at these points, 80 
again emphasising the indirect nature of iRBC clearance as measure of current drug killing. 81 
 82 
The observed reductions in parasitaemia following drug treatment are invariably referred to 83 
as “parasite” clearance rates. In reality, clinical observations consist of counts of the number 84 
(actually the density) of iRBC which may contain live, dead or dying malaria parasites (24). 85 
This was noted by Kremsner and Krishna (25) who discussed clearance times after drug 86 
treatment and concluded that “a circulating parasite might be alive, injured (fatally), or dead 87 
in these circumstances”. Similarly, Watkins, Woodrow and Marsh (26) state that “the stained 88 
blood film, although it can be accurate and reproducible, provides only a total parasite count 89 
from which viable and nonviable counts cannot be differentiated”. The difference between 90 
“parasite clearance” and “iRBC clearance” is not merely semantic: the fact that iRBCs must 91 
be cleared (i.e. removed from the blood circulation by the spleen or by other host 92 
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mechanisms), rather than the parasite being cleared directly, is important. An iRBC presents a 93 
complex target to the human immune system implying that immunity will play a large role in 94 
the dynamics of clearance. The impact of host immunity can therefore reduce both the 95 
sensitivity and specificity of iRBC clearance as a diagnostic of drug effectiveness. The term 96 
“iRBC clearance rate” will be used in this manuscript in place of the more usual “parasite 97 
clearance rate” to emphasise what is actually being observed and measured. Readers will be 98 
aware that the terms are synonymous, but the former is more technically correct. The 99 
principle research question addressed herein is to consider the likely relative contributions of 100 
drug effectiveness and host defence mechanisms to the iRBC clearance rates observed in 101 
patients after ACT treatment, and to evaluate the use and application of iRBC clearance rates 102 
as research and surveillance tools.  103 
 104 
Methods 105 
 106 
Failure rates to ACTs are currently very low (1) so it is not statistically feasible to compare in 107 
vivo iRBC clearance rates in patients where drug treatment was successful versus patients 108 
where treatment was unsuccessful (for example, Ashley et al. (7) reported a cure rate of 98% 109 
in their study of 1,241 patients in South East Asia). Even if such a comparison were possible, 110 
immunity is likely to affect both therapeutic outcome and iRBC clearance rates, causing a 111 
correlation that could be mistaken for causality (as explained later). These circumstances 112 
dictate that pharmacological modelling be used to simulate ACT treatment and to investigate 113 
the properties of iRBC clearance rates when used as an indicator of drug effectiveness. 114 
 115 
Pharmacological model  116 
 117 
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A pharmacological model of artemisinin drug treatment incorporating drug stage specificity 118 
was constructed based upon the standard model first implemented by Hoshen et al. (27), and 119 
used by several subsequent authors (e.g. (23, 28)). Its construction and calibration is detailed 120 
in the Supplemental Material, part 1. Briefly, the parasite population is split into 48 121 
developmental ‘age-bins’ corresponding to each hour of the Plasmodium falciparum 48-hour 122 
life cycle. At each hour post-treatment, the drug kills some parasites in each age-bin (if the 123 
drug is present and active against that developmental age-bin) and surviving parasites are 124 
then moved into the next development stage. Parasites in the 48th age-bin rupture to release 125 
new parasites (default of 10 per schizont) and the latter are moved into the 1st age-bin. This 126 
enables the number of parasites in each age-bin to be tracked each hour post-treatment.  127 
 128 
Drug kill rate units are per hour and are obtained from the more familiar PRR48 for the 129 
methodological reasons explained is the SI around Equations S1.1.  As a reference to interpret these 130 
kill rates on an hourly scale,   kill rates of 0.19, 0.14 and 0.096, are equivalent to PRR48 of 10-4 131 
(because e-48x0.19=10-4), 10-3 and 10-2 respectively assuming all parasite stages are equally sensitive. In 132 
fact, not all stages are equally sensitive which is why the kill rates for the sensitive stages have to be 133 
increased to compensate for the lack of killing in the non-sensitive stages to maintain the same 134 
PRR48 values (see SI for details). 135 
 136 
Previous work (e.g. (27, 28)) typically did not track the fate of parasites once dead within the 137 
iRBCs as the studies focussed on drug effectiveness and the clearance dynamics of dead 138 
parasites were of no interest. A simple extension was added to this basic methodology: rather 139 
than assuming killed parasites are instantaneously removed from the circulation, those killed 140 
while inside circulating iRBCs are moved into a ”dead-but-circulating” population of iRBCs, 141 
which is cleared by the host at a clearance rate determined by host factors. Parasites killed 142 
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while in sequestered iRBCs are assumed to die in situ and do not re-enter the circulation (see 143 
discussion in Supplemental Material, part 1). The same strategy has been used previously by 144 
other authors. Hietala and colleagues (29), following Gordi et al. (30), fitted a ‘spleen 145 
clearance’ compartment to their pharmacokinetic/pharmacodynamic (PK/PD) analyses of 146 
patients treated with the ACT artemether-lumefantrine. They found that inclusion of a spleen 147 
clearance rate of 0.26 per hour (equivalent to a half-life of 2.7 hours) as reported in Gordi et 148 
al. (30) provided a better fit to the data. The term “spleen clearance rate” will be used here to 149 
quantify the rate at which iRBC containing dead or dying parasites are removed from the 150 
circulation by host defences. It is synonymous with the “spleen and macrophage clearance 151 
rate” used previously by Hietala, Gordi and colleagues (29, 30). The use of “spleen clearance 152 
rate” is for clarity and to avoid any ambiguity with iRBC clearance but readers will realise 153 
that iRBC clearance is a complex drug-dependent process that also depends on immunity, the 154 
spleen and possibly other host factors (and, in fact, patients without spleens can still clear 155 
their infection) and that “spleen clearance rate” is simply a convenient term covering all these 156 
factors; a more detailed discussion of host defences and access to the primary literature can 157 
be found elsewhere (e.g.(18)). We also assume that all circulating iRBCs are counted to 158 
obtained clearance as guidelines for microscopy in research settings do not distinguish 159 
between live and dead parasites (31). There are variants in this procedure. Parasites may be 160 
scored as dead/alive based on their morphology (although this is particularly difficult in vivo 161 
where circulating parasites are predominantly early ring stages) and clearance rates would 162 
subsequently be based on the reduction of ‘live’ parasites (20). Alternatively, direct counts 163 
may be replaced by molecular surrogates such as quantitative PCR and clearance quantified 164 
as the reduction in qPCR signal (e.g. (32)). 165 
 166 
Sensitivity analysis of iRBC clearance rates and drug effectiveness 167 
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 168 
The parameterisation of the methodology is described in Supplemental Material, part 1. 169 
Individual parameter values were varied systematically within calibrations to isolate the 170 
effect of changing single parameters (see later discussion of Figure 1). A sensitivity analysis 171 
was then performed by simulating 5,000 patients treated with either dihydroartemisinin-172 
piperaquine (DHA-PPQ) or artesunate-mefloquine (AS-MQ). Each patient had an initial 173 
parasite number of 1012 which may be uniformly distributed across all age bins, or may 174 
predominantly be in early ring stages. Note that the initial parasite number has no effect on 175 
the subsequent shape of dynamics in the model output except to alter the time until 176 
circulating parasites become undetectable. The following four factors were varied during the 177 
sensitivity analysis: the artemisinin kill rate, the duration of artemisinin killing after treatment 178 
(specified as an integer, i.e. number of hours), the partner drug kill rate and the spleen 179 
clearance rate (see Supplemental Material, text surrounding Equation S1.2 for technical 180 
details of the drug killing). The correlation was measured between these four factors and drug 181 
effectiveness and iRBC clearance rates. Drug effectiveness was quantified using the 182 
conventional metric of parasite reduction ratio (PRR48) which is the ratio of the number of 183 
parasites present at start of treatment, divided by the number remaining 48 hours later. More 184 
effective treatments will kill more parasites and, consequently, will result in a higher PRR48.  185 
 186 
Impact of dosing regimen and increasing parasite cell cycle time on iRBC clearance rates 187 
 188 
Concerns overs about future effectiveness of ACTs, and the lack of readily available 189 
alternatives, have driven attempts to increase clinical effectiveness through changes in their 190 
deployment regimens. One such strategy is to increase the dosage given. This is predicted to 191 
result in increased duration of drug killing after treatment ((33) and later discussion of Figure 192 
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1). Another strategy is to split the dosage regime. The specific example of splitting the 193 
standard three day regimen of DHA-PPQ into twice-daily dosing was then investigated 194 
(details in Supplemental Material, part 1). Theory, and intuition, suggest the main impact will 195 
be on artemisinin, rather than partner drug,  killing (33, 34) so simulations were run with and 196 
without PPQ killing, the latter to remove the complicating factors of PPQ drug action. 197 
 198 
There has been speculation (e.g. (35)) that mutations in the P. falciparum kelch propeller 199 
domain (K13) may be associated with increased cell cycle duration. The K13 mutations 200 
appear to have reduced drug sensitivity during the hypersensitive early ring stages (36). The 201 
likely impact of a simple increase in  cell cycle time on iRBC clearance rates was 202 
investigated by increasing cell cycle time from 48 hours to 57.6 hours (a 20% increase) or to 203 
72 hours (a 50% increase). The impact of simultaneously increasing cell cycle time and 204 
reducing drug sensitivity was investigated by modifying the hypersensitive profile (see 205 
Supplemental Material, part 1) so that malaria parasites became insensitive to artemisinin 206 
during their hyper-sensitive early ring age-bins.  207 
 208 
Results 209 
 210 
The model recovered the main features of iRBC clearance dynamics that occur after 211 
artemisinin treatment, i.e. the characteristic linear decline in circulating iRBC number 212 
following artemisinin treatment was routinely observed. Moreover, this linearity was not 213 
affected by additional killing periods that occur in subsequent doses of artemisinins (e.g. 214 
Figure 2). 215 
 216 
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The results from the sensitivity analysis of PRR48 and iRBC clearance rates are shown on 217 
Table 1. The correlation is high between artemisinin kill rate, partner drug kill rate, duration 218 
of artemisinin killing and overall drug effectiveness measured as PRR48. However, negligible 219 
correlations were observed between these factors and iRBC clearance rates (recall that PRR48 220 
is the change in the total number of living parasites, both circulating and sequestered, 221 
whereas iRBC clearance is change in number of circulating iRBC that may contain either 222 
living or dead parasites). The main correlation for iRBC clearance rates is with spleen 223 
clearance rate, indicating that the latter is the dominant force determining iRBC clearance 224 
rates and almost entirely obscures any impact of artemisinin kill rate, partner drug kill rate, 225 
duration of artemisinin killing or PRR48 on iRBC clearance rates. Drug effectiveness, 226 
measured as PRR48, is essentially invisible: the largest correlation between PRR48 and iRBC 227 
clearance is 0.04 in the simulated datasets whereas the correlation between spleen clearance 228 
rate and iRBC clearance is >0.93 in all simulations and generally very close to 1. These are 229 
correlation coefficients and squaring their values quantifies the proportion of the variability in 230 
iRBC clearance rates that may be explained by the differing factors. Drug effectiveness 231 
parameters therefore explains a maximum of 0.162 = 2.5% of the variation in the iRBC 232 
clearance rates (Table 1), while spleen clearance rates explain between 0.932 = 86% and 12 = 233 
100% of the variability. 234 
 235 
Mutations that affect intrinsic drug susceptibility of malaria parasites were found to act in two main 236 
ways (we later discuss the possible impact of changes in cell cycle duration). Firstly, such changes 237 
may alter the duration of artemisinin killing after treatment (33), although this will have little impact 238 
on iRBC clearance rates unless the duration of killing falls to less that around 2 hours (Figure 1, 239 
Panel A), despite the large impact of reduced duration of killing on drug effectiveness (Figure 1, 240 
Panel B). This clearly shows that iRBC counts by microscopy are highly insensitive to changes in 241 
artemisinin drug effectiveness and can only detect changes once parasite susceptibility to artemisinin 242 
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has fallen to very low levels. Even a reduction in the duration of killing by 83% from 6 hours to 1 243 
hour post-treatment was predicted to only reduce iRBC clearance rates by around 10% (i.e. from 244 
around 0.22 to 0.20) despite drug killing (PRR48) falling by factors of up to 1010. 245 
 246 
The second way in which the impact of mutation(s) on intrinsic parasite susceptibility to artemisinin 247 
may be manifested is in reductions in kill rates. In the model, reduced artemisinin kill rates were 248 
found to exhibit little impact on iRBC clearance rate until they reached very low levels. Mutation(s) 249 
that reduce artemisinin kill rates below around 20% of wild-type levels may become 250 
detectable as reduced iRBC clearance rates although, as might be expected intuitively, the 251 
magnitude of this reduced iRBC clearance depends on the stage distribution of parasites at 252 
time of treatment (Figure 1 Panel C). Once again, this low sensitivity occurs despite the huge 253 
impact that changing artemisinin kill rate has on drug effectiveness (Figure 1, Panel D). 254 
 255 
One common method of increasing drug effectiveness in the face of resistance is to increase 256 
the amount of drug given to patients (within the limits of toxicity). Pharmacologically, this 257 
increases the duration of artemisinin killing after treatment and its predicted impact has 258 
already been shown on Figure 1: dose increases which extend the duration of killing for more 259 
than around 2 or 3 hours post treatment are unlikely to be detected using iRBC clearance 260 
rates (Figure 1, Panel A), despite the huge changes in drug effectiveness that arises from such 261 
dose increases (Figure 1, Panel B). This suggests that iRBC clearance rates have low 262 
sensitivity for monitoring the impact of drug regimen change based on dose-escalation.  263 
 264 
An alternative method to increase drug efficacy, that does not involve increasing the total 265 
dose, is to change the dosing regimen. The consequences of splitting the dose of DHA-PPQ 266 
into a twice daily dosing regimen are shown in detail on Figure 2. As predicted (34), the drug 267 
effectiveness varied substantially (by a factor of 108), the PRR48 being 1.7 × 104, 9.8 × 107, 268 
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1.8 × 108 and 1.0 × 1012 for Panels A, B, C, and D respectively in Figure 2. Despite these 269 
differences in ACT effectiveness, the clearance rates were identical in each panel of Figure 2, 270 
suggesting clearance rates are unable to detect even huge changes in drug effectiveness. The 271 
impact of the additional doses of artemisinin are quite clear on total parasitaemia (Panel B 272 
versus Panel A and Panel D versus Panel C) but the effects of spleen clearance rates and the 273 
constant background killing of PPQ obscure these differences to the extent that observed 274 
iRBC clearance rates (blue lines) are not sufficiently sensitive to detect even the substantial 275 
impact on total drug killing that occurs as the regimen is split and given twice daily. In this 276 
case, the slope of the observed iRBC clearance (blue line) measured on its linear portion 277 
between 18 and 48 hours was 0.26 per hour in all cases despite the large differences in  278 
artemisinin killing rates (black lines). 279 
 280 
The impact of extending the parasites cell cycle time from 48 hours to 57.6 hours (a 20% 281 
increase) or to 72 hours (a 50% increases) are shown on Table S1 in Supplemental Material. 282 
Changes in iRBC clearance rates are small and occur only when spleen clearance rates are 283 
relatively fast, i.e. with half-lives in the region of 2 hours. Moreover the impact is 284 
unpredictable, sometimes slowing clearance rates and sometimes increasing them. The largest 285 
alterations was of the latter, i.e. clearance rates increasing from 0.34 per hour to 0.43 per hour 286 
when cycle time was extended from 48 to 72 hours (Table S1 in Supplemental Material, i.e. 287 
the example of DHA-PPQ with an isosensitive profile used to treat an early ring stage 288 
infection in a patent whose endogenous clearance rate was 0.35 per hour). It therefore seems 289 
unlikely that small to moderate increases in cell cycle time could explain the increasing 290 
clearance rates currently being observed in South East Asia. Note that this is only a small 291 
pilot exploration designed to reveal whether extending cell cycle time has a consistently large 292 
impact. It was assumed that the increase in cell cycle length affected all age-bins equally, 293 
13 
 
while a more nuanced analysis would investigate more complex patterns where the increase 294 
in cell cycle length was due to changes in time spent in specific age bins (such as early rings) 295 
(35). 296 
 297 
Discussion 298 
 299 
The results presented above have such wide ranging implications that the Discussion will be 300 
split into four distinct sections to maintain focus and to enable readers to navigate through the 301 
separate strands of discussion. 302 
 303 
Consistency with previous results 304 
 305 
It is widely recognised that immunity affects iRBC clearance rate, high immunity being 306 
associated with faster clearance. A review by White (18) specifically noted that “As 307 
immunity increases [...] parasite clearance is accelerated so the slopes of parasite clearance 308 
curves become steeper”. Commentators are also aware of this effect. Uhlemann and Fidock 309 
(9), for example, stated that “The shift in parasite clearance rates with time could have 310 
various causes, including waning immunity as interventions reduced exposure of patients to 311 
parasites”. It has long been known that increasing failure rates to other drugs can be due to 312 
decreased immunity rather than increased resistance. For example, Greenhouse and 313 
colleagues (37) concluded that increasing drug failure rates in their longitudinal study was 314 
due to decreasing levels of immunity rather than changes in parasites drug resistance levels. 315 
Similarly,  Lopera-Mesa et al. (38) reported that clearance rates in their study sites most 316 
likely reflected differences in patients’ immune status. The results presented above show that 317 
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immunity, which clearly contributes to spleen clearance rates, is most likely the dominant 318 
factor determining iRBC clearance rates.  319 
 320 
Clearance rates have been used to quantify drug effectiveness and in surveillance 321 
programmes designed to detect drug resistance (e.g. (2-4, 6, 7, 39, 40)) but see (15-17) for 322 
critical appraisals of these usages. The theoretical underpinning of their use in this context 323 
follows this simple logic. The presence of detectable parasites in a patient three days after 324 
treatment is known to be a risk factor for drug failure (e.g. (41)). The iRBC clearance rates 325 
partially determine whether or not parasites are detectable at Day 3 (initial parasitaemia also 326 
plays a role). Consequently, slower parasite clearance rates must be associated with increased 327 
risk of Day 3 positivity and therefore be associated with increased failure rates. This logic 328 
appears robust but note the last step, i.e. that slower clearance rates are associated with 329 
increased failures not necessarily that they cause failures.. It is a basic tenet of data analysis 330 
that association does not imply causation. It is highly plausible that this association arises 331 
from a common factor, human immunity (42), which affects both iRBC clearance rate and 332 
eventual probability of treatment failure, and that interpreting this association as causation is 333 
logically unsound. Another complicating factor is that malaria infections, especially in high 334 
transmission areas, are genetically heterogeneous and clearance rate of the majority of iRBC 335 
may not reflect the ultimate fate of the infection (treatment success/failure) as the latter may 336 
depend on the presence/absence of low-density resistance genotypes present as minority 337 
clones in the infections (e.g.(43)). 338 
 339 
Our simulations allow a detailed consideration of the dynamics of iRBC clearance. This 340 
suggests the underlying reason why host immunity is the main determinant of iRBC 341 
clearance rates. Artemisinins are present at active concentrations for around 4 to 6 hours post-342 
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treatment. The proportion of circulating parasites killed by artemisinin during this period will 343 
be called the initial kill burst (IKB). Clearance measures are typically delayed for 6 to 20 344 
hours after treatment to allow the log-linear decline in iRBC to become established and 345 
measurable (e.g. (21)). This delay is therefore likely to largely exclude the factor we are 346 
really interested in measuring, the extent of artemisinin killing in the IKB: artemisinin killing 347 
occurs before iRBC clearance rates are estimated so makes no contribution to the subsequent 348 
clearance rate of iRBC. The subsequent rate of decline of circulating iRBCs then most likely 349 
measures how rapidly host clearance mechanism remove iRBCs containing dead or dying 350 
parasites killed during the IKB. 351 
 352 
This interpretation also explains the clinical observation that subsequent doses of artemisinin 353 
(indicated as horizontal red lines in Figure 2) have no further impact on clearance rates. The 354 
dynamics can be understood as the interactions between the three factors that determine 355 
iRBC clearance dynamics, i.e. spleen clearance rates, sequestration rates and new-merozoite-356 
release rates. These rates differ substantially. Spleen clearance rates have half-lives in the 357 
region of 2 to 5 hours. Sequestration rates depend on the number and development stages of 358 
circulating parasites, but half have been sequestered by age-bin 14 so half-lives may be 359 
approximated as 14 hours (although this is more for illustration as it forces an exponential 360 
decline onto a much complex sequestration regimen; see Supplemental Material, part 1). 361 
Finally, sequestered parasites have a half-life of around (48-14) /2 = 17 hours before their 362 
schizonts release new merozoites into the circulation. Sequestration and new-merozoite-363 
release rates are therefore both substantially slower than spleen clearance rates but these rates 364 
must be scaled by the number of parasites in each group. The dynamics can therefore be 365 
understood as follows: the first few hours of non-linearity occur because the IKB has to 366 
establish a sufficient number of iRBC with dead parasites such that the spleen clearance rates 367 
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completely dominate the other two factors and hence dominate the overall dynamics of iRBC 368 
clearance. Subsequent doses of artemisinin may kill a large proportion of the remaining 369 
viable circulating parasites but this will be invisible because, as noted, above, it is impossible 370 
to distinguish circulating iRBC with live, dead or dying parasites (26). This interpretation is 371 
supported by clinical data from Wootton and colleagues (44) who estimated the proportion of 372 
viable parasites among circulating iRBC to be <0.5% following treatment with 2 or 4 mg/kg 373 
of artesunate, a clear demonstration that treatment with ACTs results in a huge pool of dead 374 
iRBC awaiting spleen clearance.   375 
 376 
Implications for assessing drug effectiveness 377 
 378 
One of the main opportunities to increase drug effectiveness is by regimen changes, typically 379 
increasing the total dosage given to patients and/or changing dosing regimen patterns. This is 380 
particularly important given current concerns that artemisinin resistance may be spreading 381 
and threating the therapeutic effectiveness of ACTs.  382 
 383 
The first option to increase drug effectiveness is to increase the artemisinin dose; this 384 
essentially increases the duration of killing after treatment (33). Figure 1, Panels A and B 385 
suggest that iRBC clearance rates will be unable to detect even substantial increases in 386 
artemisinin killing that occur above a duration of killing threshold of around 2 to 3 hours 387 
post-treatment. It is possible to convert this threshold into one based on drug intake doses. 388 
We investigated what DHA intake dosages would result in 2 or 3 hours of parasite killing 389 
using standard PK/PD modelling with our default dihydroartemisinin (DHA) parameters 390 
(Table 1 of (45)). An intake dose of ~0.2 mg/kg DHA resulted in around two hours duration 391 
of artemisinin killing after treatment, while an intake dose of ~0.5 mg/kg resulted in a 392 
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duration of killing of around three hours (for reference, the currently-recommended DHA 393 
dosage is 4 mg/kg giving a duration of killing of around 5 to 6 hours (Figure 3 of (34)). 394 
Hence the threshold of 2 to 3 hours on Figure 1, Panel A equates to a DHA intake dose of 395 
around 0.2 to 0.5 mg/kg. In practice, this threshold will be higher because there is substantial 396 
PK/PD variation in nature and so a considerable proportion of patients treated with 0.5 mg/kg 397 
of DHA would have durations of killing much shorter than 3 hours. Using a rule of thumb of 398 
3-fold variation in PK/PD (45, 46) suggests the threshold of detection, above which 399 
additional artemisinin killing will not be detected by iRBC clearance rates (Figure 1, Panel 400 
A), will probably lie somewhere in the region of 3 × 0.5 = 1.5 mg/kg. Angus et al. (47) 401 
concluded that no further increase in iRBC clearance rates occur above doses around 2 402 
mg/kg. They administered AS which has a higher molecular weight than DHA (384 versus 403 
284 g/mol, respectively), meaning their 2 mg/kg of artesunate was equivalent to a 2 × 404 
284/384 = 1.5 mg/kg dose of DHA. Their results are therefore highly consistent with the 405 
threshold identified in our model (although visual inspection of their raw data (Figures 2 and 406 
3 of (47)) suggests this threshold for detection of increased AS killing by iRBC clearance 407 
rates may plausibly be lower than 2 mg/kg). Similarly, Saunders and colleagues (48) reported 408 
no difference in iRBC clearance times or rates when dosing with AS at 2, 4 or 6 mg/kg; again 409 
these results are highly consistent with our model prediction that all three doses would lie 410 
above the detection threshold. Angus et al. (47) asserted that no further increase in iRBC 411 
clearance rates occurred above 2 mg/kg because higher doses had no further impact on drug 412 
killing. A clear alternative interpretation is that their metric, iRBC clearance rates, simply 413 
lacked the sensitivity required to detect further increases in parasites killing (Figure 1, Panel 414 
A). If the latter interpretation is true, it clearly indicates an opportunity to increase ACT drug 415 
effectiveness through the relatively simple expedient of increasing artemisinin dose, at least 416 
within the levels restrained by toxicity. 417 
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 418 
Another strategy to improve drug effectiveness is to split the standard dose and give it more 419 
frequently. In ACT this essentially means switching from a single daily dose to twice-daily 420 
dosing (as is currently done for artemether-lumefantrine (AM-LF), noting that the need for 421 
twice daily dosing is driven by the LF rather than the AM component). The total dose 422 
remains unchanged so the twice-daily doses contain half the drug content of the once-daily 423 
doses. Pharmacological modelling of clinical data suggested this could increase drug 424 
effectiveness (28). Our more recent quantitative PK/PD modelling (34) identified its 425 
mechanistic basis (it arises from a law-of diminishing returns in antimalarial drug dosing 426 
(33)) and showed that split dosing is a far more effective strategy for improving artemisinin 427 
effectiveness than simply increasing the total amount of artemisinin given. Figure 2 illustrates 428 
the comparative dynamics of daily and twice-daily dosing in more detail based on current 429 
DHA-PPQ regimens and separates out the effect of artemisinin alone (top row) with the 430 
effect of including the partner drug PPQ (bottom row). The clear conclusion is that the split-431 
dose strategy will result in increased drug effectiveness but that iRBC clearance rates 432 
primarily reflect patient immune status so were similar in all cases and unable to detect the 433 
changes in drug effectiveness. Note that this is robust over a range of calibrations and partner 434 
drugs; the latter have such long half-lives that our model output suggests that the impact of 435 
split dosing is immaterial for partner drugs, it is the artemisinin killing that increases so 436 
dramatically with split dose regimens. 437 
 438 
Unfortunately, attempts to implement ACT split-dose regimen changes are currently hindered 439 
by a trial (14) that evaluated twice-daily regimen changes using iRBC clearance rates as an 440 
indicator of drug effectiveness and reported no difference in clearance rates. A key 441 
operational question is therefore to decide whether this is a valid measure of drug efficacy, or 442 
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whether it reflects an inherent lack of sensitivity in the metric being used to estimate 443 
effectiveness. We therefore suggest an alternative interpretation of the results of Das et al. 444 
(14): No differences in clearance rates occurred between different regimens because the 445 
overwhelming impact of immunity on clearance rates would have obscured differences in 446 
drug killing between the regimens. The huge costs of developing a new drug and the potential 447 
risks to human subjects as drugs enter clinical development, make it operationally and 448 
ethically essential to use well-validated clinical indicators of likely efficacy. It seems 449 
essential that the malaria community now re-considers drug regimen changes as a means to 450 
offset, or even prevent, the early stages of resistance (34). 451 
 452 
 453 
Implications for monitoring for drug resistance 454 
 455 
The most widespread application of clearance rates has occurred in surveys of ACTs in South 456 
East Asia where reduced iRBC clearance rates have been routinely interpreted as indicating 457 
reduced drug effectiveness due to the onset of artemisinin “resistance” (see (49) for a recent 458 
access to the literature and Supplemental Material, part 2 for a discussion on genetic analysis 459 
of iRBC clearance rates). The studies have used both artemisinin monotherapy (e.g. (7, 39, 460 
40)) and artemisinins within ACTs (e.g. (3, 50)); the much higher potency of the artemisinin 461 
component against circulating stages (compared to its partner drugs within ACTs) means that 462 
artemisinins are the main determinants of clearance rates within ACTs so the two types of 463 
studies, monotherapies and ACTs, can be viewed as equivalents in terms of their clearance 464 
phenotypes (18, 34). The results presented above show that iRBC clearance rates are a highly 465 
insensitive surveillance tool for resistance as they can only detect resistance if it is 466 
sufficiently strong (or immunogenic, see below) that virtually all parasites within circulating 467 
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iRBC survive treatment. This is presumably the case with the newly-identified K13 mutations 468 
(51) which appear to virtually remove parasite hyper-sensitivity in their early ring stages 469 
allowing its detection through increased iRBC clearance rates. Note also that it is possible 470 
that some partner drugs may kill some circulating parasites which would produce a pool of 471 
dead parasites within iRBC that could partially obscure the effects of changing artemisinin 472 
sensitivity on iRBC clearance rates (see discussion of the three iRBC clearance factors 473 
described above). Consequently, it could be the case that artemisinin resistance may be 474 
detected as increased clearance time in ACTs whose partner drugs do not kill circulating 475 
parasites, while no such increase in clearance may be noted in ACTs whose partner drugs do 476 
kill some circulating iRBC. Hence a strategy of using artemisinin monotherapy to measure 477 
iRBC clearance rates (prior to the partner drug being administered) is a preferable strategy. 478 
 479 
 480 
Clearance rates of iRBCs also have potentially very low specificity as other factors, notably 481 
falling patient immunity, may cause slower clearance and be erroneously interpreted as 482 
indicating “resistance”. At least three reviews (15-17) have pointed out that declining levels 483 
of immunity may have contributed to decreased clearance rates observed in South East Asia 484 
and have been confused with changes in drug sensitivity levels; see also (52,53) for examples 485 
of the subsequent discussion.  Given the concerns over the impact of possible artemisinin 486 
resistance (op. cit.) it seems imperative to properly design a surveillance strategy and 487 
recognise the dangers of over-reliance on iRBC clearance rates as the sole surveillance tool. 488 
The properties of the K13 mutations, principally their resistance to artemisinins while in 489 
circulating early-ring forms (54) combined with possible changes in progression through 490 
early (but not later) stages of the parsites’ nominal 48-hour cycle (35), seem ready-made to 491 
allow their detection through reduced iRBC clearance rate. However there is no guarantee 492 
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that other artemisinin resistance mutations will be so obliging, and indeed, it is possible that 493 
they may already be present but remain undetected; for example mutations in the ap2-mu 494 
gene have been shown to modulate artemisinin sensitivity of both murine and human malaria 495 
(55, 56). Plowe (57), for example, noted that K13 need not be the only artemisinin 496 
“resistance” gene and we require a surveillance method to detect other mutations. As stressed 497 
here, iRBC clearance rates are unlikely to be sufficiently sensitive to detect all manifestations 498 
of artemisinin resistance and other surveillance tools, such as screening for genetic sweeps 499 
(58, 59) and in vitro sensitivity assays, need to be more widely recognised and used in 500 
surveillance for resistance. 501 
 502 
Conclusions 503 
 504 
It is widely recognised that immunity makes a potentially substantial contribution to iRBC 505 
clearance rates, and that fitting a “dead-awaiting clearance” class of iRBC improves model fit 506 
to clinical data (29, 30). It therefore seems extraordinary that there has been no objective 507 
investigation of the impact of host immunity on the use of iRBC clearance rates as 508 
surveillance tools for drug resistance and as efficacy tools for evaluating drug regimen 509 
changes. This was the impetus for the work presented here. Our model output suggests that 510 
host clearance processes, such as immunity, completely dominate the iRBC clearance 511 
phenotype unless artemisinin effectiveness is extremely low. This makes iRBC clearance 512 
rates highly insensitive to changes in underlying parasite drug sensitivity and to drug 513 
effectiveness cause by regimen changes. 514 
 515 
The purpose of this study had been to try and open a more objective debate about the use of 516 
iRBC clearance rates post-treatment as proxy measures of drug effectiveness and resistance. 517 
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It is possible, perhaps even likely, that iRBC clearance rates reflect the level of an individual 518 
patient’s acquired immunity to malaria (e.g. (38)), with the degree of parasite resistance or 519 
drug effectiveness being effectively invisible against this background. The World Health 520 
Organization set up an action plan to contain artemisinin resistance in 2011 (60). It was 521 
laudable to act on this initial evidence but no serious attempts appear to have been made in 522 
the subsequent few years to validate the use of the parasite clearance rate as a good metric of 523 
parasite resistance (15-17). The use of iRBC clearance rates as measures of drug 524 
effectiveness is particularly worrying, with the likely consequence that regimen changes 525 
capable of increasing drug effectiveness may be ignored as they have little impact on iRBC 526 
clearance rates ((34); Figure 2 of this manuscript). 527 
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Table 1. Sensitivity analysis:  correlation coefficients between drug effectiveness 739 
(measured as parasite reduction ratio, PRR48), infected red blood cell clearance rates 740 
(iRBCcr), and underlying drug and host parameters. Model parameters investigated were 741 
the duration of artemisinin killing after dosing (Art. duration), the magnitude of artemisinin 742 
killing rate (Art. kill rate), the magnitude of partner drug kill rate (Partner kill rate), and the 743 
spleen clearance rate of circulating iRBC containing dead parasites. The drugs investigated 744 
are (A) dihydroartemisinin-piperaquine (DHA-PPQ) and (B) artesunate-mefloquine (AS-745 
MQ). Two artemisinin sensitivity profiles are investigated (the iso- and hyper-sensitivity 746 
profiles) and starting stage distribution of parasites may be either uniform or early ring stage. 747 
See Supplemental Material, part 1 for more explanation and technical details.  748 
  749 
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 750 
(A) DHA-PPQ 751 
Artemisinin 
sensitivity profile 
Isosensitivity Hypersensitivity 
Parasite 
distribution at time 
of treatment 
uniform early ring uniform early ring 
Outcome: PRR48 iRBCcr PRR48 iRBCcr PRR48 iRBCcr PRR48 iRBCcr
Art. Duration (hr) 0.18 0.05 0.17 0.02 0.18 0.08 0.21 0.08 
Art kill rate (hr-1) 0.19 0.05 0.18 0.08 0.19 0.10 0.22 0.15 
Partner kill rate 
(hr-1) 
0.14 0.03 0.14 0.02 0.15 0.04 0.14 0.09 
PRR48 - -0.01 - 0.00 - 0.04 - 0.03 
Spleen clearance 
rate (hr-1) 
- 0.99 - 0.99 - 0.99 - 0.93 
 752 
(B) AS-MQ 753 
Artemisinin 
sensitivity profile 
Isosensitivity Hypersensitivity 
Parasite 
distribution at time 
of treatment 
uniform early ring uniform early ring 
Outcome: PRR48 iRBCcr PRR48 iRBCcr PRR48 iRBCcr PRR48 iRBCcr
Art. Duration (hr) 0.19 0.02 0.20 0.01 0.19 0.01 0.19 0.07 
Art kill rate (hr-1) 0.21 0.04 0.22 0.05 0.20 0.06 0.21 0.16 
33 
 
Partner kill rate 
(hr-1) 
0.14 0.00 0.15 0.02 0.13 0.01 0.14 0.11 
PRR48 - 0.01 - 0.00 - 0.01 - 0.04 
Spleen clearance 
rate (hr-1) 
- 1.00 - 0.99 - 0.99 - 0.93 
  754 
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Figure 1. The lack of sensitivity of clearance rates to changes in artemisinin killing.  755 
 756 
Changes in artemisinin killing may arise in two ways. Firstly, the duration of killing post-757 
treatment will alter if parasites evolve resistance (measured as a reduced concentration at 758 
which drug killing is half its maximum value) or if the intake dose given to patients is 759 
changed.  The left hand column shows the effect of varying the duration of artemisinin killing 760 
from 1 to 8 hours after each dose (the default value being 6 hours). Panel (A) shows the 761 
impact on observed infected red blood cell (iRBC) clearance rate. Panel (B) shows the impact 762 
on drug effectiveness quantified as the parasite reduction ratio (PRR48). Secondly, the 763 
artemisinin kill rate may changes as parasites evolve resistance. The right hand column shows 764 
the effect of varying the artemisinin kill rate from 10% to 120% of the default value. Panel 765 
(C) shows the impact on observed iRBC clearance rate. Panel (D) shows the impact on drug 766 
effectiveness quantified as the PRR48. 767 
 768 
The two drugs investigated were artesunate-mefloquine (AS-MQ) and dihydroartemisinin-769 
piperaquine (DHA-PPQ). Parasite sensitivity to AS and DHA follows “isosensitivity” or 770 
“hypersensitivity” PD profiles, respectively, and the dosing was either once- or twice-daily. 771 
All simulations had spleen clearance rates set to 0.231 per hour (equivalent to a clearance 772 
half-life of 3 hours). See Supplemental Material, part 1 for technical details. Note that the red 773 
and green dotted lines are superimposed on panels B and D, as are the blue and black dotted 774 
lines. Note also that PRR48 does not fall to zero as partner drug killing alone would achieve a 775 
PRR48 of around 103.  776 
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 777 
Figure 2. An example of the lack of sensitivity of parasite clearance rates to changes in 778 
drug effectiveness caused by regimen changes. 779 
 780 
Blue lines are “parasite clearance rates”, i.e. the number of circulating infected red blood 781 
cells (iRBCs) containing either live or dead parasites. Green lines are the number of 782 
circulating iRBCs containing live parasites. Black lines are total parasitaemias, i.e. the total 783 
number of live parasites in both circulating and sequestered iRBCs. Red horizontal bars 784 
indicate when DHA is present at active concentrations and the grey horizontal band indicates 785 
the parasite detection limit below which circulating parasites cannot be realistically detected 786 
or counted by routine microscopy. The drug simulated is dihydroartemisinin (DHA) alone 787 
(top row) and in combination with piperaquine (PPQ) (bottom row). The left hand column is 788 
the drug(s) given once per day over three days, and the right hand column is an alternative 789 
regimen when the same total amount of drug(s) is given but split into twice-daily doses given 790 
over three days. Spleen clearance rate of iRBCs containing dead parasites is assumed to be 791 
0.26 per hour as estimated in Gordi et al. (30), equivalent to a spleen clearance half-life of 2.7 792 
hours. The drug sensitivity profiles follow the hypersensitivity model, i.e. where early ring 793 
stages are hypersensitive to DHA. The infection at start of treatment was primarily in early 794 
ring stages (mean = 10.5 hours, standard deviation = 5 hours). The modelling details are 795 
provided in Supplemental Material, part 1. 796 
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